Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology and Medical Oncology Fellowship, Medicine, Duke University School of Medicine 2011 - 2015
  • Internal Medicine Chief Resident, Medicine, Duke University School of Medicine 2012 - 2013
  • Categorical Internal Medicine Residency, Medicine, Duke University School of Medicine 2008 - 2011
  • M.D., Indiana University School of Medicine 2008
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2015 - 2017
  • Medical Instructor in the Department of Medicine, Medicine, General Internal Medicine, Medicine 2012 - 2013
• Research
• 

  Selected Grants

  • TOP 1705 awarded by Bristol-Myers Squibb Company 2018 - 2023
  • SPI-POZ-202 awarded by Spectrum Pharmaceuticals, Inc 2017 - 2022
  • M15-534 awarded by AbbVie Inc. 2017 - 2022
  • Bayer 16044 awarded by Bayer HealthCare AG 2017 - 2021
  • A screening protocol to determine tumor antigen expression and HLA sub-type ofr eligibility determination for clinical trials evaluating the safety and efficacy of Autologous T Cell expressing enhance awarded by Adaptimmune Limited 2016 - 2021
  • Adaptimmune MAGE A-4 awarded by Adaptimmune Limited 2018 - 2020
  • Genentech GO29537 awarded by F. Hoffmann-La Roche Ltd 2015 - 2020
  • A phase I/IIa study of BMS986148 a Mesothelin directed antibody drug conjugate in subjects with select advanced solid tumors awarded by Bristol-Myers Squibb Company 2015 - 2020
  • An Open label phase II study evaluatint Traztuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in patients who have advanced cancer awarded by Genentech, Inc. 2016 - 2020
  • Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2020
  • mRNA-4157-P101 awarded by Moderna Therapeutics, Inc. 2017 - 2019
  • Adaptimmune MAGE awarded by Adaptimmune Limited 2018 - 2019
  • A phase Ib study of combination Regorafenib with PF-03446962 in patient with refactory metastatic colorectal cancer or G awarded by Pfizer, Inc. 2013 - 2019
  • First-in-human dose escalation of TEW-7197 monotherapy in subjects with advanced stage solid tumors awarded by MedPacto, Inc 2014 - 2019
  • Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer awarded by V Foundation for Cancer Research 2016 - 2018
  • Evaluation of Tumor Infiltrating Lymphocytes in Resected Non Small Cell Lung Cancer awarded by Lung Cancer Initiative of North Carolina 2015 - 2018
  • Lilly H9H-MC-JBEF awarded by Eli Lilly and Company 2016 - 2018
  • Blood-based Biomarker Profiling for TEW-7197 awarded by MedPacto, Inc 2016 - 2018
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • DeMaio, A, Clarke, JM, Dash, R, Sebastian, S, Wahidi, MM, Shofer, SL, Cheng, GZ, Li, X, Wang, X, and Mahmood, K. "Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma." Journal of Bronchology & Interventional Pulmonology 26, no. 2 (April 2019): 96-101.  Full Text
    • Pabla, S, Conroy, JM, Nesline, MK, Glenn, ST, Papanicolau-Sengos, A, Burgher, B, Hagen, J, Giamo, V, Andreas, J, Lenzo, FL, Yirong, W, Dy, GK, Yau, E, Early, A, Chen, H, Bshara, W, Madden, KG, Shirai, K, Dragnev, K, Tafe, LJ, Marin, D, Zhu, J, Clarke, J, Labriola, M, McCall, S, Zhang, T, Zibelman, M, Ghatalia, P, Araujo-Fernandez, I, Singavi, A, George, B, MacKinnon, AC, Thompson, J, Singh, R, Jacob, R, Dressler, L, Steciuk, M, Binns, O, Kasuganti, D, Shah, N, Ernstoff, M, Odunsi, K, Kurzrock, R, Gardner, M, Galluzzi, L, and Morrison, C. "Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients." Journal for Immunotherapy of Cancer 7, no. 1 (February 2019): 27-null.  Full Text
    • Shariff, AI, Syed, S, Shelby, RA, Force, J, Clarke, JM, D'Alessio, D, and Corsino, L. "Novel cancer therapies and their association with diabetes." Journal of Molecular Endocrinology 62, no. 2 (February 2019): R187-R199. (Review)  Full Text
    • Conroy, JM, Pabla, S, Nesline, MK, Glenn, ST, Papanicolau-Sengos, A, Burgher, B, Andreas, J, Giamo, V, Wang, Y, Lenzo, FL, Bshara, W, Khalil, M, Dy, GK, Madden, KG, Shirai, K, Dragnev, K, Tafe, LJ, Zhu, J, Labriola, M, Marin, D, McCall, SJ, Clarke, J, George, DJ, Zhang, T, Zibelman, M, Ghatalia, P, Araujo-Fernandez, I, de la Cruz-Merino, L, Singavi, A, George, B, MacKinnon, AC, Thompson, J, Singh, R, Jacob, R, Kasuganti, D, Shah, N, Day, R, Galluzzi, L, Gardner, M, and Morrison, C. "Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors." Journal for Immunotherapy of Cancer 7, no. 1 (January 24, 2019): 18-null.  Full Text
    • Velikova, G, Williams, LJ, Willis, S, Dixon, JM, Loncaster, J, Hatton, M, Clarke, J, Kunkler, IH, Russell, NS, Alhasso, A, Adamson, D, Algurafi, H, Allerton, R, Anandadas, C, Bahl, A, Barraclough, L, Barrett-Lee, P, Barthakur, U, Bedi, C, Beresford, M, Bishop, J, Blackman, G, Bliss, P, Bloomfield, D, Blunt, M, Branson, T, Brazil, L, Brunt, A, Chakrabarti, A, Chittalie, A, Churn, M, Cleator, S, Crellin, P, Danwata, F, De-Silva-Minor, S, Dhadda, A, Eicholz, A, Fernando, I, Forrest, J, Fraser, J, Goodman, A, Grieve, R, Griffin, M, Hadaki, M, Hall, A, Hicks, J, Hignett, S, Hogg, M, Jyothirmayi, R, Khan, M, Konstantinos, G, Kumar, S, Lawton, P, Lee, D, Lewinski, C, Lim, C, Locke, I, Lumsden, G, Lupton, S, Magee, B, Marshall, J, Masinghe, S, McGregor, C, McLennan, M, Memtsa, P, Milanovic, D, Misra, V, Mithal, N, Mukesh, MB, Neal, A, Needleman, S, Persic, M, Quigley, M, Raj, S, Riddle, P, Ritchie, D, Roberts, F, Robson, P, Roe, H, Rolles, M, Shah, N, Sharma, R, Sherwin, E, Simmonds, P, Skailles, G, Skaria, S, Soe, W, Sripadam, R, Stevens, A, Stockdale, A, Storey, N, Syndikus, I, Thorp, N, Upadhyay, S, and Varughese, M. "Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial." The Lancet Oncology 19, no. 11 (November 1, 2018): 1516-1529.  Full Text
    • Marano, AL, Clarke, JM, Morse, MA, Shah, A, Barrow, W, Selim, MA, Hall, RP, and Cardones, AR. "Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy." The British Journal of Dermatology (September 23, 2018).  Full Text
    • Clarke, JM, George, DJ, Lisi, S, and Salama, AKS. "Immune Checkpoint Blockade: The New Frontier in Cancer Treatment." Targeted oncology 13, no. 1 (February 13, 2018): 1-20.  Full Text
    • Yi, JS, Ready, N, Healy, P, Dumbauld, C, Osborne, R, Berry, M, Shoemaker, D, Clarke, J, Crawford, J, Tong, B, Harpole, D, D'Amico, TA, McSherry, F, Dunphy, F, McCall, SJ, Christensen, JD, Wang, X, and Weinhold, KJ. "Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 23, no. 24 (December 2017): 7474-7482.  Full Text
    • Bedoya, A, Glisinski, K, Clarke, J, Lind, RN, Buckley, CE, and Shofer, S. "Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases." The American Journal of Case Reports 18 (July 31, 2017): 842-846.  Full Text
    • Clarke, JM, Wang, X, and Ready, NE. "Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?." Translational Lung Cancer Research 4, no. 6 (December 2015): 804-808.  Full Text
    • Hatch, AJ, Clarke, JM, Nixon, AB, and Hurwitz, HI. "Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress." Cancer journal (Sudbury, Mass.) 21, no. 4 (July 2015): 322-326. (Review)  Full Text
    • Lyman, GH, Bohlke, K, Khorana, AA, Kuderer, NM, Lee, AY, Arcelus, JI, Balaban, EP, Clarke, JM, Flowers, CR, Francis, CW, Gates, LE, Kakkar, AK, Key, NS, Levine, MN, Liebman, HA, Tempero, MA, Wong, SL, Somerfield, MR, Falanga, A, and American Society of Clinical Oncology, . "Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 6 (February 2015): 654-656.  Full Text
    • Clarke, JM, Hurwitz, HI, and Rangwala, F. "Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective." Cancer treatment reviews 40, no. 9 (October 2014): 1065-1072. (Review)  Full Text
    • Clarke, JM, Hurwitz, HI, and Rangwala, F. "Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinician's perspective." Cancer Treatment Reviews 40, no. 9 (2014): 1065-1072.  Full Text
    • Clarke, JM, and Hurwitz, HI. "Understanding and targeting resistance to anti-angiogenic therapies." J Gastrointest Oncol 4, no. 3 (September 2013): 253-263.  Full Text  Link to Item
    • Clarke, JM, and Hurwitz, HI. "Targeted inhibition of VEGF receptor 2: an update on ramucirumab." Expert Opinion on Biological Therapy 13, no. 8 (August 2013): 1187-1196. (Review)  Full Text
    • Lyman, GH, Khorana, AA, Kuderer, NM, Lee, AY, Arcelus, JI, Balaban, EP, Clarke, JM, Flowers, CR, Francis, CW, Gates, LE, Kakkar, AK, Key, NS, Levine, MN, Liebman, HA, Tempero, MA, Wong, SL, Prestrud, AA, Falanga, A, and American Society of Clinical Oncology Clinical Practice, . "Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 17 (June 2013): 2189-2204. (Review)  Full Text
    • Clarke, JM, and Armstrong, AJ. "Novel therapies for the treatment of advanced prostate cancer." Curr Treat Options Oncol 14, no. 1 (March 2013): 109-126. (Review)  Full Text  Link to Item
    • Clarke, JM, and Hurwitz, HI. "Ziv-aflibercept: binding to more than VEGF-A--does more matter?." Nature Reviews. Clinical Oncology 10, no. 1 (January 2013): 10-11.  Full Text
    • Mis, L, and Clarke, JM. "Ipilimumab-induced pneumonitis: A case report." Journal of Pharmacy Technology 29, no. 2 (January 1, 2013): 94-98.  Full Text
    • Clarke, JM, Morse, MA, Lyerly, HK, Clay, T, and Osada, T. "Adenovirus vaccine immunotherapy targeting WT1-expressing tumors." Expert Opin Biol Ther 10, no. 6 (June 2010): 875-883. (Review)  Full Text  Link to Item
    • Clarke, JM, and Helft, P. "Long-term survival of a woman with well differentiated papillary mesothelioma of the peritoneum: A case report and review of the literature." Journal of Medical Case Reports 4 (2010).  Full Text
    • Struck, A, Howard, T, Chiorean, EG, Clarke, JM, Riffenburgh, R, and Cardenes, HR. "Non-ampullary duodenal adenocarcinoma: Factors important for relapse and survival (Journal of Surgical Oncology (2009) 100, 2, (144-148))." Journal of Surgical Oncology 100, no. 5 (October 1, 2009): 434-null.  Full Text
    • Struck, A, Howard, T, Chiorean, EG, Clarke, JM, Riffenburgh, R, and Cardenes, HR. "Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival." Journal of Surgical Oncology 100, no. 2 (August 2009): 144-148.  Full Text

  • Conference Papers

    • Yi, J, Clarke, JM, Healy, P, Wang, XF, Shoemaker, D, and Onaitis, MW. "Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC)." 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 2, 2017 - June 7, 2017.: AMER SOC CLINICAL ONCOLOGY, March 1, 2017.  Link to Item
    • Clarke, JM, Blobe, GC, Strickler, JH, Uronis, HE, Zafar, Y, Morse, M, Dropkin, E, Howard, L, O'Neill, M, Rushing, CN, Niedzwiecki, D, Watson, H, Arrowood, C, and Hurwitz, H. "Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL)." : American Society of Clinical Oncology (ASCO), May 20, 2016.  Full Text
    • Clarke, JM, Pang, H, Starr, MD, Hatch, AJ, Kindler, HL, O'Reilly, EM, Innocenti, F, Venook, AP, Hurwitz, H, and Nixon, AB. "Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance)." : American Society of Clinical Oncology (ASCO), January 20, 2015.  Full Text
    • Liu, Y, Clarke, JM, Starr, MD, Brady, JC, Pang, H, Rushing, C, Alvarez, D, Adams, BJ, Theuer, CP, Hurwitz, H, and Nixon, AB. "Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial." : American Society of Clinical Oncology (ASCO), May 20, 2014.  Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.